Cushman & Wakefield plc (CWK)

NYSEReal EstateReal Estate - ServicesSnapshot 2026-10-23

$11.83-2.23%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Cushman & Wakefield plc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-3.7%

+10% or more+5%0%−5%−10% or less

1.72 → 1.66 EPS · FY ending Dec 31, 2027 · 7 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	3.06B
EPS	—	0.609
FY 2026 · Annual
Revenue	—	11.15B
EPS	—	1.459
Eps growth	18%–23%non-GAAP	—
FY 2027 · Annual
Revenue	—	11.82B
EPS	—	1.66

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Positive cash flow from operations by FY28	They plan to improve cash flow, targeting $800M by 2028.	Improving	Free cash flow falls below $800M in FY28	Free cash flow: $74.1M FY2026-Q2; GAAP. Published target: >=800 USD_MILLIONS. Target period is not explicitly aligned with this observation. Source published Aug 5, 202674,100,000 USD · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage debt and avoid worsening off-balance sheet obligations	A supporting condition in Cushman & Wakefield plc's published investment case. The stated target is No material increase in off-balance sheet obligations.	Under Pressure	New material off-balance sheet obligations created	New off-balance sheet obligation filed 2026-06-15 Form 8-K filed June 15, 2026, explicitly reports the creation of a new off-balance sheet obligation. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improvement from recent lows	A primary condition in Cushman & Wakefield plc's published investment case. The stated target is Operating income recovers above $58.7M quarterly run rate.	Improving	Operating income remains below $58.7M quarterly	Operating income: $134.2M FY2026-Q2; GAAP. Published target: Operating income recovers above $58.7M quarterly run rate. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026134,200,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 32bfeb54-71cf-46ed-bf24-59c522fdea33. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of the 3 supplied transcript quarters. Operating income was $58.7 million in 2026-Q1 and $134.2 million in 2026-Q2; year-over-year operating income growth was 30% and 9%, respectively. Operating income improved, but the lower latest-quarter growth rate means progress is positive with a slower year-over-year pace. Delivery assessment Oct 24, 2026
Revenue at or above $10.3B in FY26	A primary condition in Cushman & Wakefield plc's published investment case. The stated target is >=10.3 USD_BILLIONS.	Intact	Revenue falls below $10.3B in FY26	Revenue: $2.763B FY2026-Q2; GAAP. Published target: >=10.3 USD_BILLIONS. Target period is not explicitly aligned with this observation. Source published Aug 5, 20262,762,600,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 32bfeb54-71cf-46ed-bf24-59c522fdea33. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$1.66

$1.71 → $1.66 · observed estimates

FY2027 revenue$11.82B

$9.09B → $11.82B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$1.71	$9,091,156,375	7 / 6
2026-07-25	$1.71	$9,091,156,375	7 / 6
2026-07-26	$1.72	$11,805,601,257	7 / 6
2026-07-27	$1.66	$11,832,572,680	12 / 7
2026-07-28	$1.66	$11,832,572,680	12 / 7
2026-07-29	$1.72	$11,805,601,257	7 / 6
2026-07-30	$1.66	$11,832,572,680	12 / 7
2026-07-31	$1.72	$11,805,601,257	7 / 6
2026-08-01	$1.72	$11,805,601,257	7 / 6
2026-08-02	$1.66	$11,832,572,680	12 / 7
2026-08-03	$1.66	$11,832,572,680	12 / 7
2026-08-04	$1.72	$11,805,601,257	7 / 6
2026-08-05	$1.66	$11,832,572,680	12 / 7
2026-08-06	$1.72	$11,805,601,257	7 / 6
2026-08-07	$1.72	$11,831,351,099	7 / 6
2026-08-08	$1.71	$11,882,029,830	12 / 7
2026-08-09	$1.71	$11,882,029,830	12 / 7
2026-08-10	$1.71	$11,882,029,830	12 / 7
2026-08-11	$1.72	$11,831,351,099	7 / 6
2026-08-12	$1.72	$11,831,351,099	7 / 6
2026-08-13	$1.72	$11,917,012,830	12 / 7
2026-08-14	$1.72	$11,831,351,099	7 / 6
2026-08-15	$1.72	$11,831,351,099	7 / 6
2026-08-16	$1.72	$11,831,351,099	7 / 6
2026-08-17	$1.72	$11,831,351,099	7 / 6
2026-08-18	$1.72	$11,831,351,099	7 / 6
2026-08-19	$1.72	$11,831,351,099	7 / 6
2026-08-20	$1.73	$11,869,008,151	7 / 7
2026-08-21	$1.73	$11,869,008,151	7 / 7
2026-08-22	$1.73	$11,869,008,151	7 / 7
2026-08-23	$1.73	$11,869,008,151	7 / 7
2026-08-24	$1.73	$11,869,008,151	7 / 7
2026-08-25	$1.73	$11,869,008,151	7 / 7
2026-08-26	$1.73	$11,869,008,151	7 / 7
2026-08-27	$1.73	$11,869,008,151	7 / 7
2026-08-28	$1.73	$11,869,008,151	7 / 7
2026-08-29	$1.72	$11,885,445,363	7 / 7
2026-08-30	$1.72	$11,885,445,363	7 / 7
2026-08-31	$1.72	$11,885,445,363	7 / 7
2026-09-01	$1.72	$11,885,445,363	7 / 7
2026-09-02	$1.72	$11,885,445,363	7 / 7
2026-09-03	$1.73	$11,885,445,363	7 / 7
2026-09-04	$1.72	$11,885,445,363	7 / 7
2026-09-05	$1.72	$11,885,445,363	7 / 7
2026-09-06	$1.72	$11,885,445,363	7 / 7
2026-09-07	$1.72	$11,885,445,363	7 / 7
2026-09-08	$1.72	$11,885,445,363	7 / 7
2026-09-09	$1.72	$11,885,445,363	7 / 7
2026-09-10	$1.72	$11,885,445,363	7 / 7
2026-09-11	$1.72	$11,885,445,363	7 / 7
2026-09-12	$1.72	$11,885,445,363	7 / 7
2026-09-13	$1.72	$11,885,445,363	7 / 7
2026-09-14	$1.72	$11,885,445,363	7 / 7
2026-09-15	$1.72	$11,885,445,363	7 / 7
2026-09-16	$1.72	$11,885,445,363	7 / 7
2026-09-17	$1.72	$11,885,445,363	7 / 7
2026-09-18	$1.72	$11,885,445,363	7 / 7
2026-09-19	$1.72	$11,885,445,363	7 / 7
2026-09-20	$1.72	$11,885,445,363	7 / 7
2026-09-21	$1.72	$11,885,445,363	7 / 7
2026-09-22	$1.72	$11,885,445,363	7 / 7
2026-09-23	$1.72	$11,885,445,363	7 / 7
2026-09-24	$1.72	$11,885,445,363	7 / 7
2026-09-25	$1.72	$11,885,445,363	7 / 7
2026-09-26	$1.72	$11,885,445,363	7 / 7
2026-09-27	$1.72	$11,885,445,363	7 / 7
2026-09-28	$1.72	$11,885,445,363	7 / 7
2026-09-29	$1.72	$11,885,445,363	7 / 7
2026-09-30	$1.72	$11,885,445,363	7 / 7
2026-10-01	$1.72	$11,885,445,363	7 / 7
2026-10-02	$1.72	$11,885,445,363	7 / 7
2026-10-03	$1.72	$11,885,445,363	7 / 7
2026-10-04	$1.72	$11,885,445,363	7 / 7
2026-10-05	$1.72	$11,885,445,363	7 / 7
2026-10-06	$1.72	$11,885,445,363	7 / 7
2026-10-07	$1.72	$11,885,445,363	7 / 7
2026-10-08	$1.72	$11,885,445,363	7 / 7
2026-10-09	$1.72	$11,885,445,363	7 / 7
2026-10-10	$1.72	$11,885,445,363	7 / 6
2026-10-11	$1.72	$11,885,445,363	7 / 6
2026-10-12	$1.72	$11,885,445,363	7 / 6
2026-10-13	$1.72	$11,885,445,363	7 / 6
2026-10-14	$1.72	$11,885,445,363	7 / 6
2026-10-15	$1.71	$11,838,098,050	7 / 6
2026-10-16	$1.71	$11,838,098,050	7 / 6
2026-10-17	$1.71	$11,838,098,050	7 / 6
2026-10-18	$1.70	$11,822,377,936	7 / 6
2026-10-19	$1.70	$11,822,377,936	7 / 6
2026-10-20	$1.69	$11,822,377,936	7 / 6
2026-10-21	$1.69	$11,822,377,936	7 / 6
2026-10-22	$1.69	$11,822,377,936	7 / 6
2026-10-23	$1.66	$11,821,242,200	7 / 6
2026-10-24	$1.66	$11,821,242,200	7 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	5
2026-06-01	8	5
2026-07-01	7	5
2026-08-01	7	5
2026-09-01	8	5
2026-10-01	8	4

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Positive cash flow from operations by FY28Free cash flow: $74.1M
Manage debt and avoid worsening off-balance sheet obligationsPublished status: Under Pressure
Operating income improvement from recent lowsOperating income: $134.2M
Revenue at or above $10.3B in FY26Revenue: $2.763B

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-35.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cushman & Wakefield plc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CWK is a growth-and-execution story in a rate-sensitive Real Estate sector, with elevated risk rather than a clearly durable compounder profile. Its long-term thesis is currently intact: revenue and adjusted earnings have grown, and management has raised its 2026 guidance, though a recent earnings miss and a run of misses leave execution quality fragile.

What's priced into Cushman & Wakefield plc

The valuation evidence is mixed: CWK is described as cheap versus peers, while a separate measure shows a premium versus peers. The priced-in assessment is tagged justified, with low fragility and no evidence that the market is assuming an unusually optimistic setup.

What the fundamentals likely do

Near term, revenue growth has been solid, with 11% year-over-year growth in both 2026-Q1 and Q2, while Services growth eased from 9% to 8%. Adjusted EPS rose 17% year over year in Q2, and management raised its 2026 adjusted EPS growth guidance; however, the latest earnings miss and consecutive-miss history keep execution risk elevated. Debt repayments are meaningful progress on borrowing costs, though delivery on capital structure remains mixed.

What Cushman & Wakefield plc hinges on

The multi-year view depends on CWK sustaining growth and delivering its raised earnings guidance without reversing course, since a guidance cut could damage management credibility. Near term, lower interest rates and continued strong results from sector peers could support the sector backdrop, while persistent sector headwinds remain a constraint.